Literature DB >> 10849333

Bronchial granular cell tumor with osteopontin and osteonectin expression: a case report.

Y Jin1, N Kuroda, S Kakiuchi, Y Yamasaki, E Miyazaki, Y Hayashi, M Toi, K Naruse, M Hiroi, H Enzan.   

Abstract

The case of a 52-year-old Japanese man with bronchial granular cell tumors with osteopontin and osteonectin expression is reported here because there have been few investigations of their expression in benign tumors. He was admitted because of sudden hematemesis. A bronchoscopic examination revealed a lobulated polypoid tumor located in the left and right bronchi. Histologically, most tumor cells had abundant granular eosinophilic cytoplasm and were immunoreactive for S-100, neuron-specific enolase (NSE), CD68 and vimentin. Moreover, osteopontin-positive tumor cells were randomly distributed in the tumor tissue, but few stromal cells were positive. In contrast, osteonectin was mainly expressed in the peripheral tumor cells and was also distributed in the stromal cells. Blood vessels at the tumor border in which osteonectin-positive tumor cells were distributed, proliferated moderately. These results suggest that osteopontin and osteonectin may play a role in the progression of granular cell tumors and in the interaction between the tumor and host or angiogenesis around the tumor, respectively.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10849333     DOI: 10.1046/j.1440-1827.2000.01048.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  2 in total

1.  A rare case of a pulmonary granular cell tumor presenting as a coin lesion.

Authors:  Tomoko Hosaka; Satoshi Suzuki; Hiromichi Niikawa; Jotaro Shibuya; Takashi Suzuki; Masashi Handa
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2003-03

2.  Clinicopathological characteristics and gene analysis of pulmonary granular cell tumor in three cases and a systematic review.

Authors:  Hai Zhang; Fang Hu; Xueyan Zhang; Yanwei Zhang; Changhui Li; Yuqing Chen; Feng Li
Journal:  Transl Cancer Res       Date:  2020-08       Impact factor: 1.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.